UORSY (Ukrorgsyntez Ltd.)

What UORSY (Ukrorgsyntez Ltd.) does

UORSY (Ukrorgsyntez Ltd.) is a privately held, Kyiv-based specialty chemical company that provides synthetic organic chemistry products and services to the global drug-discovery market. Founded in 2001 (per the firm's own website; a separate data block lists 2008) and operating with approximately 30 employees, the company focuses on small-molecule screening libraries, chemical building blocks, and fee-for-service custom synthesis for pharmaceutical, biotechnology, agrochemical, and academic customers.

The company's core product portfolio comprises (i) a Tangible Building Blocks database of over 15 million synthetically accessible entries with a validated >76% synthesis success rate, distributed partly through the Chem-Space marketplace under partnership with Enamine Ltd; (ii) Screening Compounds — 680,000+ in-stock compounds for 1-week delivery and 1.9 million compounds for 3-week delivery, including the proprietary New Generation Screening Library built on sp3-enriched, lead-like structures; (iii) 28 in-stock Targeted Libraries and 7 Fragment subsets (covalent, fluorinated, saturated, shape-diverse, soluble, general, selected) curated via cheminformatics filters; and (iv) Custom Synthesis services spanning gram-to-kilogram building blocks, compound libraries, reference standards, and impurity standards, executed with specialized reaction capabilities (ozonolysis, high-pressure hydrogenation, SF4/DAST fluorination, flow chemistry, asymmetric synthesis) and biweekly progress reporting.

UORSY monetizes through three primary streams: catalog sales of in-stock screening compounds, building blocks, targeted libraries and fragments (one-time license/transactional pricing); custom synthesis on a fee-for-service, risk-bearing basis where the company absorbs failure costs and only invoices upon confirmed delivery and quality; and targeted quote-based enterprise engagements routed via a global, registration-gated B2B website with direct email sales channels ([email protected], [email protected], [email protected]). The go-to-market is sales-led and low-touch at the top of funnel — requiring site registration — with mid-funnel direct customer communication for quotation, which is typically prepared within 2–3 days.

Name

UORSY (Ukrorgsyntez Ltd.)

Legal name

Ukrorgsyntez Ltd.

Website

https://uorsy.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

UORSY (Ukrorgsyntez Ltd.) is a Kyiv-based, privately held specialty chemical company that supplies synthetic organic chemistry products — including 15M+ building blocks, 680K+ in-stock screening compounds, 28 targeted libraries, 7 fragment subsets, and custom synthesis services — to pharmaceutical, biotechnology, agrochemical, and academic drug-discovery customers worldwide.

Ownership category

akta.pro rank

Product category

Drug Discovery Specialty Chemicals

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG)

Keywords

• Screening compound libraries
• Chemical building blocks
• Custom synthesis services
• Drug discovery compounds
• Medicinal chemistry services

Headquarters

HQ city

Kyiv

HQ country

Ukraine

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Infrastructure

Revenue model

1. Custom Synthesis Services: Fee-for-service custom synthesis of building blocks, compound libraries, reference standards for biological research, and impurity reference standards. Customers receive quotation within 2-3 days and are only invoiced after confirmation of safe receipt and quality. The company absorbs all risks of synthesis failure.
2. Screening Compounds and Building Blocks Sales: Sale of screening compounds from in-stock libraries with various delivery timeframes (1-week, 3-week). Also includes sale of tangible building blocks through the Chem-Space platform.
3. Targeted and Fragment Libraries: Sale of targeted libraries (28 in-stock) and fragment libraries (7 in-stock subsets) for hit follow-up and cherry picking applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Ukrorgsyntez Ltd. (UORSY) is a specialty synthetic organic chemistry company that manufactures and sells chemical building blocks, screening compound libraries, fragment libraries, and targeted libraries for small-molecule drug discovery. The company also offers fee-for-service custom synthesis of building blocks, compound libraries, reference standards, and impurity reference standards from gram to kilogram scale. Customers include pharmaceutical, biotechnology, agrochemical, and academic research organizations worldwide.

Product overview

UORSY (Ukrorgsyntez Ltd.) offers a comprehensive portfolio of chemical compounds for small molecule drug discovery, organized into three main product categories: Screening Compounds, Fragments and Targeted Libraries, and Custom Synthesis services. The screening portfolio includes over 1.2 million compounds (1-week delivery) and 1.9 million compounds (3-week delivery), including the unique New Generation Screening Library with sp3-enriched lead-like molecules. The Fragment Libraries include seven subsets (Covalent Fragments, General Fragments, F-fragments, Fragments with Solubility, Saturated Fragments, Selected Fragments, and Shaped Fragments), while the Targeted Libraries comprise 28 disease or target-focused collections spanning oncology (Wnt Pathway Modulators, Tubulin Inhibitors, Hippo Pathway Modulators), neuroscience (DCLK1 Modulators, DYRK1A/B Modulators, CNS-permeable Compounds), and anti-infectives (Antibacterial, Antiviral), among others. The Tangible Building Blocks database contains 15 million synthetically accessible building blocks searchable on Chem-Space. Custom Synthesis services provide fee-for-service production of building blocks, compound libraries, reference standards, and impurity standards. All products comply with quality standards including minimum 90% purity by 1H NMR.

Differentiator

Problem solved

Functional benefit

Brands

• Enamine-UORSY: Cooperation between UORSY and Enamine Ltd for tangible building blocks

Products and services

• Tangible Building Blocks A database of 15,000,000 synthetically accessible chemical building blocks with validated chemistry and validated reagents, featuring a >76% synthesis success rate. Searchable online on Chem-Space and available as 24 popular medicinal chemistry class sets for drug discovery researchers.
• Screening Compounds (1-Week Delivery) Over 1.2 million screening compounds assembled from in-house building blocks, with more than 85% having drug-like physicochemical profiles and more than 35% having lead-like profiles. Available as 20k, 10k, and 5k diversity sets for high-throughput screening programs.
• New Generation Screening Library (3-Week Delivery) A collection of sp3-enriched lead-like molecules with exceptional structural quality and diversity, featuring rigid, unique cores decorated with pharmacophoric fragments including peptidic bonds, amino, and hydroxyl groups. Designed under the 'Escape from Flatland' concept for improved drug-like properties.
• Custom Synthesis Services Fee-for-service custom synthesis of building blocks, compound libraries, reference standards for biological research, impurity reference standards, and coordination compounds in gram to kilogram scale. Features biweekly progress reports, no-charge-if-failed risk terms, and IP ownership transfer to customers.
• Fragment Libraries Seven fragment-like in-stock subsets (Covalent Fragments, General Fragments, F-fragments, Fragments with Solubility, Saturated Fragments, Selected Fragments, Shaped Fragments) compliant with Rule of Three and filtered for PAINS, designed for fragment-based drug discovery hit identification.
• Targeted Libraries Twenty-eight in-stock targeted libraries including Agrochemicals, Antibacterial, Antiviral, Autophagy, CNS-permeable, Covalent Modifiers, DCLK1 Modulators, DYRK1A/B Modulators, GPCR Modulators, Hedgehog Pathway Modulators, Hippo Pathway Modulators, Ion Channel Modulators, Kinase Modulators, Lead-like Compounds, Macrocycles, Mixed Shapes, Polyhydroxy Compounds, PPI Modulators, Protease Inhibitors, Saturated Compounds, SARMs, SERMs, SH2 Domain Modulators, Steroid-like, Transporters Modulators, Tubulin Inhibitors, Unique Compounds, and Wnt Pathway Modulators for hit follow-up and cherry picking.
• Tangible Building Blocks Sets Twenty-four popular medicinal chemistry classes extracted from the representative Tangible Building Blocks set, including alcohols, aliphatic acids, aldehydes, boronic acids, sulfonyl halides, alkyl halides, aromatic compounds, benzyl halides, amines, heterocycles, ketones, and more, offered as curated subsets.
• Lead-like Compounds Diversity selections of 35k, 20k, and 10k lead-like compounds from the pool of lead-like compounds, designed as better starting points for drug discovery projects compared with drug-like molecules.
• Unique Compounds Library Library of 3 sets (30k, 10k, and 1k) of unique compounds with no close analogues in purchasable chemical space (8 million), featuring favorable physicochemical profiles and lacking overused motifs.
• Kinase Modulators Library Library selected using Tanimoto similarity analysis comparing in-stock compounds with known kinase modulating compounds from ZINC15, filtered from Pan-Assay Interference and boring chemistry substances.
• Antiviral Library Lead-like compounds selected using ligand-based approach for antiviral drug discovery, filtered for PAINS and overused substances removal.
• Antibacterial Library Selected based on similarity to known antibacterial agents (ECFP4 fingerprints, Tanimoto score > 0.7) and novel chemotypes with favorable physicochemical profiles.
• Agrochemicals Library Combining popular agro-like motifs and similarity analysis to known agro-active reference sets, including compounds with multiple F/Cl atoms, S-containing heterocycles, oxo-azoles, cyclopropanes, and other agrochemical motifs.
• Ion Channel Modulators Selected from lead-like stock using ligand-based approach for ion channel modulation drug discovery, filtered to remove PAINS, toxic, and overused substances.
• GPCR Modulators Selected from lead-like compounds using ligand-based approach for G-protein coupled receptor targeting, filtered to remove PAINS, toxic, and overused substances.
• Covalent Modifiers Small molecules with functional groups or warheads including beta-lactams, epoxides, alkyl halides, acrylamides, Michael acceptors, and over 30 other chemical classes, for target identification, imaging, or inhibition.

Quantifiable outcome

• Over 85% of screening compounds have drug-like physicochemical profiles; more than 35% have lead-like profiles
• +1 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Enamine LtdcoreStrategic or Co-development PartnerUORSY cooperates with Enamine Ltd for the Tangible Building Blocks product line. This partnership combines UORSY's synthetic organic chemistry expertise with Enamine's distribution capabilities through the Chem-Space platform, providing researchers with access to validated medicinal chemistry building blocks.

Scale indicators6 records

Recent moves1 record

Expansion highlights5 records

Direct peers

• Life Chemicals: Supplier of focused and targeted screening libraries, building blocks, and custom synthesis for early-stage drug discovery. Overlapping catalog, target library design philosophy, and FFS custom synthesis model.
• Combi-Blocks: US-based provider of screening compounds, building blocks, and custom synthesis serving pharma and biotech drug discovery. Closely comparable catalog model, custom synthesis offering, and target customer profile.
• Enamine Ltd. Ukraine-headquartered global leader in screening compounds and building blocks. Directly comparable in catalog scale and target customer base; also serves as UORSY's distribution partner via Chem-Space, which makes it the most relevant and most threatening peer.
• Key Organics: UK-based supplier of building blocks, screening compounds, and custom synthesis focused on drug discovery chemistry. Comparable in catalog breadth, custom synthesis service, and academic/biotech customer base.
• MolPort: Chemical marketplace aggregating building blocks and screening compounds from multiple suppliers. Competes with UORSY on buyer access and pricing transparency for the same medicinal-chemistry customer base.
• Chembridge Corporation: Long-established provider of screening libraries, building blocks, and custom synthesis for small-molecule drug discovery. Direct competitor in catalog screening compounds sold to similar pharma/biotech and academic customers.
• Princeton BioMolecular Research: Custom synthesis and library provider offering building blocks, reference standards, and screening collections. Direct competitor for fee-for-service custom synthesis and compound supply contracts with pharma/biotech.
• Otava Chemicals: Provider of screening libraries, targeted libraries, and custom synthesis services for pharmaceutical and agrochemical discovery. Comparable in offering custom and catalog medicinal-chemistry compounds to similar end users.

Emerging players

• BioAscent Discovery: Integrated drug discovery CRO offering custom synthesis, compound management, and screening services. Emerging player with comparable custom synthesis capabilities but a broader services-led model targeting small-to-mid biotech.

Broad incumbents

• Maybridge (Thermo Fisher Scientific): Now part of Thermo Fisher's chemical and reagent portfolio, Maybridge supplies screening fragments and building blocks. Competes with UORSY in catalog fragments and building blocks but as part of a much broader life-sciences platform.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/ukrorgsyntez-ltd.-uorsy-

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about UORSY (Ukrorgsyntez Ltd.)